Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baofukang is a traditional Chinese medicine (TCM) preparation, typically formulated as a vaginal suppository, used for the treatment of human papillomavirus (HPV) infections and various types of vaginitis. Its primary active components are Zedoary Turmeric Oil (derived from *Curcuma phaeocaulis*) and Borneol. Baofukang is described as having "estrogen-like" effects, which help to increase vaginal glycogen levels and improve the health of the vaginal mucosa. This action promotes the growth of beneficial Lactobacillus species, thereby restoring a healthy vaginal microenvironment that facilitates the clearance of persistent high-risk HPV (hr-HPV). Additionally, the drug exhibits direct antiviral, anti-inflammatory, and anti-fungal properties. It is frequently studied and used in clinical practice in China, both as a monotherapy and in combination with recombinant human interferon alpha-2b or probiotic preparations to enhance clinical efficacy in treating cervical HPV infections and preventing progression to high-grade intraepithelial lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baofukang.